Dr. Paul Oberstein, MD
Claim this profileNYU Langone Health
About Paul Oberstein, MD
Education:
Received an MD (Doctor of Medicine) from New York University School of Medicine in 2009.
Experience:
Serves as Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Perlmutter Cancer Center, NYU Langone Health.
Holds the position of Clinical Director of the Lymphoma Program at Perlmutter Cancer Center, NYU Langone Health.
Area of expertise
Pancreatic Cancer
Paul Oberstein, MD has run 13 trials for Pancreatic Cancer. Some of their research focus areas include:
Colorectal Cancer
Paul Oberstein, MD has run 6 trials for Colorectal Cancer. Some of their research focus areas include:
Affiliated Hospitals
NYU Langone Health
Laura And Isaac Perlmutter Cancer Center At NYU Langone
Clinical Trials Paul Oberstein, MD is currently running
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting
0 awards
Phase 2
32 criteria
Combination Therapy
for Pancreatic Cancer
The goal of this Single Arm Phase Ib clinical trial is to test standard of care chemotherapy and anti PD1 and IL1b to evaluate the safety and preliminary toxicity of this quadruplet regimen prior to resection in patients with pancreatic cancer. The main objectives it aims to answer are to: * Determine the recommended Phase II dose regimen of canakinumab and tislelizumab in combination with gemcitabine and nab-paclitaxel in patients with localized pancreatic ductal adenocarcinoma. * Estimate the proportion of patients who proceed to surgical resection. * Determine the safety and tolerability of canakimumab in combination with tislelizumab, nab-paclitaxel and gemcitabine * Assess the preliminary clinical anti-tumor activity of canakimumab in combination with tislelizumab, nab-paclitaxel and gemcitabine * Assess whether therapy has any impact on surgical options Participants will have labs drawn, CT scans, and a treatment administered consisting of: * Gemcitabine * Nab-paclitaxel * Canakinumab * Tislelizumab
Recruiting
1 award
Phase 1
10 criteria
More about Paul Oberstein, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Paul Oberstein, MD has experience with
- Gemcitabine
- Nab-paclitaxel
- Pembrolizumab
- Ipilimumab
- Canakinumab
- Nivolumab
Breakdown of trials Paul Oberstein, MD has run
Pancreatic Cancer
Colorectal Cancer
Colon Cancer
Stomach Cancer
Pulmonary hypoplasia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Paul Oberstein, MD specialize in?
Paul Oberstein, MD focuses on Pancreatic Cancer and Colorectal Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are Stage III.
Is Paul Oberstein, MD currently recruiting for clinical trials?
Yes, Paul Oberstein, MD is currently recruiting for 5 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Paul Oberstein, MD has studied deeply?
Yes, Paul Oberstein, MD has studied treatments such as Gemcitabine, Nab-paclitaxel, Pembrolizumab.
What is the best way to schedule an appointment with Paul Oberstein, MD?
Apply for one of the trials that Paul Oberstein, MD is conducting.
What is the office address of Paul Oberstein, MD?
The office of Paul Oberstein, MD is located at: NYU Langone Health, New York, New York 10016 United States. This is the address for their practice at the NYU Langone Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.